• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Citius Pharmaceuticals Inc.

    4/28/25 7:32:02 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTXR alert in real time by email
    DEFA14A 1 ea0239291-defa14a_citius.htm DEFINITIVE ADDITIONAL MATERIALS
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the Appropriate Box:

     

    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material Under Rule 14a-12

     

    Citius Pharmaceuticals, Inc.

     

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒No fee required.

     

    ☐Fee paid previously with preliminary materials:

     

    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V73961 - S13896 You invested in CITIUS PHARMACEUTICALS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Special Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 9, 2025. Get informed before you vote View the Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 26, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, 1ST FLOOR CRANFORD, NJ 07016 CITIUS PHARMACEUTICALS, INC. 2025 Special Meeting Vote by June 8, 2025 11:59 PM ET Vote in Person at the Meeting* June 9, 2025 8:00 AM EST Company’s Headquarters 11 Commerce Drive, First Floor Cranford, New Jersey 07016

     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V73962 - S13896 For 1. To approve an amendment to our Articles of Incorporation to increase the authorized number of shares from 26,000,000 to 260,000,000 and the authorized number of common shares from 16,000,000 to 250,000,000. For 2 . To approve the adjournment of the Special Meeting, if necessary, to permit further solicitation and vote of proxies, if there are not sufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to approve Proposal 1 presented at the Special Meeting . NOTE: To transact such other business as may properly come before the meeting or any adjournment thereof. Voting Items Board Recommends

     

    Get the next $CTXR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTXR

    DatePrice TargetRatingAnalyst
    12/30/2024$9.00Hold → Buy
    D. Boral Capital
    1/18/2022$4.00 → $6.00Buy
    HC Wainwright & Co.
    11/30/2021$4.00Buy
    Maxim Group
    More analyst ratings

    $CTXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Webb Carol

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dutia Suren G

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:22 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman Holubiak Myron Z

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:18 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Financials

    Live finance-specific insights

    See more

    $CTXR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

      Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

      8/12/24 8:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

      Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood

      5/29/24 8:30:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

      CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal quarter ended March 31, 2025. "As we continue to focus on the planned launch of our first FDA-approved product, LYMPHIR, through Citius Oncology, we are actively engaged in securing the necessary financing to advance our launch strategy in the coming months, as well as exploring strategic partners for Citius Oncology," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals and Citius

      5/14/25 4:30:00 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) and its oncology subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City. Conference Details:                Presentation: 3:10 pm ET on Thursday, June 5, 2025* Location: New York City Webcast: A live and archived webcast of the presentation will be available here.    A replay will be available for a limited time following the presentation on

      5/5/25 8:37:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

      CRANFORD, N.J., April 1, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of 1,739,131 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.15 per share (or pre-funded warrant in lieu thereof). The closing of the offering is expected to occur on or about April 2, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the of

      4/1/25 9:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Citius Pharmaceuticals Inc.

      10-Q - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      5/14/25 4:30:58 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      5/14/25 4:30:38 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Citius Pharmaceuticals Inc.

      DEFA14A - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      4/28/25 7:32:02 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target

      D. Boral Capital upgraded Citius Pharmaceuticals from Hold to Buy and set a new price target of $9.00

      12/30/24 7:26:29 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Citius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      1/18/22 10:01:19 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Citius Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      11/30/21 8:45:24 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

      SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      11/27/24 4:05:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Citius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      5/8/24 2:22:56 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

      SC 13G - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      1/31/24 2:08:26 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Leadership Updates

    Live Leadership Updates

    See more
    • Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

      CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

      11/5/21 9:15:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

      CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

      5/17/21 12:30:00 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care